RE: Article3 Apr 2026 17:22
The current board has delivered a 51% increase in total income for the first half of FY26, placing the company on track for its highest ever annual revenue. Under their leadership, Physiomics successfully into Biometrics, securing four new contracts and diversifying revenue streams. They demonstrated strong fiscal responsibility by securing a revised capital injection at 0.4p per share a 33% improvement over previous terms, protecting shareholder value. Replacing the entire board now would disrupt this clear growth momentum and risk losing critical sector expertise.